SCHEMBL4863797

SCHEMBL4863797

Cc1ccc(CNC(=O)N2CCCCc3ccccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.65
TP53 P04637 5/20 0.61
LMNA P02545 4/20 0.61
THRB P10828 2/20 0.59
MAPT P10636 2/20 0.57
NPC1 O15118 1/20 0.56
NFKB1 P19838 1/20 0.56
RAB9A P51151 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PDE4B Q07343 1/20 0.54
PDE4D Q08499 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PRMT5 O14744 1/20 0.53
WDR77 Q9BQA1 1/20 0.53
AVPR2 P30518 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865168 0.91 TP53 (0.71) POLBTP53LMNATHRBMAPT
SCHEMBL4868734 0.89 TP53 (0.62) POLBTP53LMNATHRBMAPT
SCHEMBL4865047 0.88 LMNA (0.75) POLBTP53LMNATHRBMAPT
SCHEMBL4869441 0.88 TP53 (0.61) TP53LMNATHRBMAPTNPC1
SCHEMBL4862542 0.88 AVPR2 (0.63) TP53LMNATHRBMAPTSMN1; SMN2
SCHEMBL4867135 0.87 LMNA (0.60) POLBTP53LMNATHRBMAPT
SCHEMBL4871802 0.87 THRB (0.76) TP53LMNATHRBMAPTNPC1
SCHEMBL4869945 0.86 TP53 (0.63) POLBTP53LMNATHRBMAPT
SCHEMBL4863710 0.84 POLB (0.74) POLBLMNATHRBAVPR2
SCHEMBL4865629 0.84 POLB (0.59) POLBTP53LMNATHRBPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 POLB 2390/4885TP53 4170/4885LMNA 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.